Brief: ExpreS2ion Biotech: Positive Safety And Efficacy Outcome Of Covid-19 Clinical Phase I/II Study For The ABNCoV2 Vaccine

ExpreS2ion Biotech Holding AB

09/08/2021 06:03

Aug 9 (Reuters) - ExpreS2ion Biotech Holding AB  EXPRS2.ST :
    * POSITIVE SAFETY AND EFFICACY OUTCOME OF THE COVID-19
CLINICAL
PHASE I/II STUDY FOR THE ABNCOV2 VACCINE
    * HEADLINE RESULTS HAS MET ITS SAFETY AND EFFICACY ENDPOINTS
    * REPORTS EXCELLENT VIRUS NEUTRALIZATION LEVELS OF UP TO 12
TIMES
HIGHER COMPARED TO LEVELS ACHIEVED AFTER COVID-19 INFECTION
    * ALL DOSAGES WERE WELL TOLERATED, AND NO SERIOUS ADVERSE
EVENTS
HAVE OCCURRED IN STUDY.

Source text for Eikon:  ID:nWkr3F4G55 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))